Transdermal ethinylestradiol/norelgestromin: a review of its use in hormonal contraception
- PMID: 15966567
- DOI: 10.2165/00024677-200302030-00005
Transdermal ethinylestradiol/norelgestromin: a review of its use in hormonal contraception
Abstract
Ethinylestradiol 20 microg/day plus norelgestromin 150 microg/day have been formulated into a transdermal patch for hormonal contraception. The predominant mechanism of action for transdermal ethinylestradiol/norelgestromin (Ortho Evra, Evra) is inhibition of ovulation by suppression of gonadotropins. It suppresses follicular development, induces changes to the endometrium that reduce the probability of implantation, and increases the viscosity of cervical mucus, which may prevent sperm penetration into the uterus. Two large randomized, nonblind efficacy studies demonstrated that transdermal ethinylestradiol/norelgestromin was as efficacious in preventing pregnancy as oral triphasic ethinylestradiol/levonorgestrel or oral ethinylestradiol/desogestrel. A large, noncomparative study also showed transdermal ethinylestradiol/norelgestromin to have good contraceptive efficacy. Moreover, in the two comparative trials, women using transdermal ethinylestradiol/norelgestromin had higher rates of perfect compliance than women using oral contraception. Age did not affect the rate of perfect compliance in women using the transdermal ethinylestradiol/norelgestromin patch, whereas the rate of compliance reduced with younger age in oral contraceptive users. Pooled results from three efficacy studies found that 1.8% of patches were replaced as a result of complete detachment and 2.9% because of partial detachment. Physical exercise, water immersion, and living in a humid climate did not affect patch adhesion. Transdermal ethinylestradiol/norelgestromin was generally well tolerated in clinical trials. The most common menstrual disturbances were breakthrough bleeding/spotting and dysmenorrhea. The incidence of discontinuation of treatment because of an adverse event was < or = 3.2%, with the most common reason being application-site reactions.
Conclusions: Transdermal ethinylestradiol/norelgestromin offers a well tolerated, effective, reversible, and easy-to-use method of hormonal contraception with an increased likelihood of compliance relative to oral contraceptives.
Similar articles
-
Ethinylestradiol + norelgestromin: new preparation. Transdermal contraception: no tangible progress.Prescrire Int. 2004 Aug;13(72):123-6. Prescrire Int. 2004. PMID: 15532134
-
New Product Review (September 2003). Norelgestromin/ethinyl oestradiol transdermal contraceptive system (Evra).J Fam Plann Reprod Health Care. 2004 Jan;30(1):43-5. doi: 10.1783/147118904322701974. J Fam Plann Reprod Health Care. 2004. PMID: 15006313
-
Transdermal contraception.Semin Reprod Med. 2001 Dec;19(4):373-80. doi: 10.1055/s-2001-18645. Semin Reprod Med. 2001. PMID: 11727179 Review.
-
The transdermal contraceptive patch: a new approach to hormonal contraception.Int J Fertil Womens Med. 2002 Mar-Apr;47(2):69-76. Int J Fertil Womens Med. 2002. PMID: 11991433 Review.
-
[A transdermal form of combined hormonal contraceptives (EVRA)].Ceska Gynekol. 2003 Oct;68(5):341-5. Ceska Gynekol. 2003. PMID: 14692356 Review. Czech.
Cited by
-
Observational, prospective, multicentre study to evaluate the effects of counselling on the choice of combined hormonal contraceptives in Italy--the ECOS (Educational COunselling effectS) study.BMC Womens Health. 2015 Sep 2;15:69. doi: 10.1186/s12905-015-0226-x. BMC Womens Health. 2015. PMID: 26329464 Free PMC article. Clinical Trial.
-
Targeting Estrogens and Various Estrogen-Related Receptors against Non-Small Cell Lung Cancers: A Perspective.Cancers (Basel). 2021 Dec 24;14(1):80. doi: 10.3390/cancers14010080. Cancers (Basel). 2021. PMID: 35008242 Free PMC article. Review.
-
Pregravid contraceptive use and fecundability: prospective cohort study.BMJ. 2020 Nov 11;371:m3966. doi: 10.1136/bmj.m3966. BMJ. 2020. PMID: 33177047 Free PMC article.
-
Managing women with gestational diabetes mellitus in the postnatal period.Diabetes Obes Metab. 2010 Jan;12(1):20-5. doi: 10.1111/j.1463-1326.2009.01147.x. Epub 2009 Sep 25. Diabetes Obes Metab. 2010. PMID: 19788432 Free PMC article. Review.
-
Construction of reporter gene assays using CWP and PDR mutant yeasts for enhanced detection of various sex steroids.Genes Environ. 2020 May 27;42:20. doi: 10.1186/s41021-020-00159-x. eCollection 2020. Genes Environ. 2020. PMID: 32514322 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources